TAP Trial at Hennepin
Trauma And Prothrombin Complex Concentrate (TAP) Trial
Trauma is the leading cause of death in those under the age of 45. The most common cause of preventable death after injury is bleeding. Kcentra® (or 4-factor prothrombin complex concentrate) is a FDA approved product that contains clotting factors. It is currently used to reverse the effects of medications given to “thin” the blood in patients, when such patients experience bleeding and/or require surgery. There is evidence that Kcentra® may reduce the chance of dying in injured patients who are not on blood-thinning medication. The Trauma And Prothrombin Complex Concentrate (TAP) Trial is a research trial to see whether Kcentra reduces the chances of people dying from their injuries because of blood loss. To learn more about the TAP Trial, visit the study's website at https://www.uab.edu/medicine/cis/tap-trial-at-hennepin
TAP Trial Survey
The researchers are asking for feedback from the Twin Cities community about this study to help determine whether the community wants us to participate in this study. Please consider completing a very brief anonymous survey hosted by the local study site. To complete the anonymous survey go to: https://uab.co1.qualtrics.com/jfe/form/SV_9Lln3tsViYM0ZnM
For More Information
For more information about the TAP Trial:
- Hennepin Main TAP Website
- Press Release: Hennepin Healthcare asking for community input on local trauma research study for blood clotting agent
- Contact Dr. Brian Driver MD at 612-873-7448 or email at brian.driver@hcmed.org